Prolactin Levels in Male Schizophrenic Patients Treated with Risperidone and Haloperidol: a Double-blind and Randomized Study

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2004 Aug 4

PMID 15289996

Citations 2

Authors

Xiang Yang Zhang

Dong Feng Zhou

Lian Yuan Cao

Pei Yan Zhang

Gui Ying Wu

Yu Cun Shen

Affiliations

Soon will be listed here.

Abstract

Rationale: There are few data from systematic, double-blind clinical trials that have compared the effect of the typical and the atypical antipsychotics on serum prolactin (PRL) levels in patients with schizophrenia.

Objectives: The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia.

Methods: Seventy-eight inpatients with a diagnosis of schizophrenia (according to DSM-III-R) were randomly assigned to 12 weeks of treatment with 6 mg/day of risperidone or 20 mg/day of haloperidol after a 2-week washout period, using a randomized, double-blind design. Clinical efficacy was determined using the positive and negative syndrome scale (PANSS). Their serum PRL was assayed by means of radioimmunometric assay (RIA) between pre-treatment and post-treatment, and compared with 30 sex-matched and age-matched normal subjects.

Results: Both risperidone and haloperidol treatment significantly increased serum PRL levels in drug-free chronic schizophrenia patients (both P<0.001). Hyperprolactinemia induced by risperidone 6 mg/kg was comparable to levels produced by haloperidol 20 mg/day. Considering dose-adjusted serum PRL levels, risperidone treatment induced a significant elevation of PRL levels compared with haloperidol treatment at the haloperidol equivalent (P<0.001). Change in PRL levels at pre-treatment and post-treatment were related to positive symptom improvement seen in the risperidone group (r=0.51, P=0.016), but not in the haloperidol group (P>0.05). Female patients showed both a higher baseline and post-treatment PRL level and a greater increase in PRL than men (all P<0.05).

Conclusions: Risperidone is associated with a robust effect on prolactin secretion in contrast to the conventional antipsychotic haloperidol. Prolactin monitoring during risperidone treatment should be performed.

Citing Articles

Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Rajkumar R Schizophr Res Treatment. 2014; 2014:175360.

PMID: 24800074 PMC: 3985293. DOI: 10.1155/2014/175360.

Management of psychosis associated with a prolactinoma: case report and review of the literature.

Ali S, Miller K, Freudenreich O Psychosomatics. 2010; 51(5):370-6.

PMID: 20833935 PMC: 3667992. DOI: 10.1176/appi.psy.51.5.370.

References

SCHOTTE A, Janssen P, Gommeren W, Luyten W, Van Gompel P, Lesage A . Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996; 124(1-2):57-73. DOI: 10.1007/BF02245606. View

David S, TAYLOR C, Kinon B, Breier A . The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000; 22(9):1085-96. DOI: 10.1016/S0149-2918(00)80086-7. View

Kaneda Y, Ohmori T . Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. Int J Neuropsychopharmacol. 2003; 6(3):247-52. DOI: 10.1017/S146114570300350X. View

Markianos M, Hatzimanolis J, Lykouras L . Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. Psychopharmacology (Berl). 2001; 157(1):55-9. DOI: 10.1007/s002130100768. View

Kleinberg D, Davis J, De Coster R, Van Baelen B, Brecher M . Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999; 19(1):57-61. DOI: 10.1097/00004714-199902000-00011. View

Halbreich U, Kinon B, Gilmore J, Kahn L . Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2002; 28 Suppl 1:53-67. DOI: 10.1016/s0306-4530(02)00112-9. View

Kapur S, Seeman P . Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001; 158(3):360-9. DOI: 10.1176/appi.ajp.158.3.360. View

Farde L, Nordstrom A, Wiesel F, Pauli S, Halldin C, Sedvall G . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49(7):538-44. DOI: 10.1001/archpsyc.1992.01820070032005. View

Kane J, Freeman H . Towards more effective antipsychotic treatment. Br J Psychiatry Suppl. 1994; (25):22-31. View

10.

Meltzer H, Fang V . The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976; 33(3):279-86. DOI: 10.1001/archpsyc.1976.01770030003001. View

11.

Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S . Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology (Berl). 2002; 162(1):63-6. DOI: 10.1007/s00213-002-1058-6. View

12.

Breier A, Malhotra A, Su T, Pinals D, Elman I, Adler C . Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999; 156(2):294-8. DOI: 10.1176/ajp.156.2.294. View

13.

Kapur S, Remington G . Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001; 52:503-17. DOI: 10.1146/annurev.med.52.1.503. View

14.

Kapur S, Mamo D . Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(7):1081-90. DOI: 10.1016/j.pnpbp.2003.09.004. View

15.

Seeman P . Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987; 1(2):133-52. DOI: 10.1002/syn.890010203. View

16.

Van Putten T, Marder S, Mintz J . Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol. 1991; 11(6):357-61. View

17.

. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 1997; 154(4 Suppl):1-63. DOI: 10.1176/ajp.154.4.1. View

18.

Petty R . Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999; 35 Suppl:S67-73. DOI: 10.1016/s0920-9964(98)00158-3. View

19.

Chou J, Douyon R, Czobor P, Volavka J, Cooper T . Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Res. 1998; 81(1):51-5. DOI: 10.1016/s0165-1781(98)00085-7. View

20.

Zhang X, Zhou D, Yuan C, Zhang P, Wu G, Shen Y . Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res. 2002; 109(3):297-302. DOI: 10.1016/s0165-1781(02)00022-7. View